Dr. Kristen Pogue discusses the VICTORIA trial.
Episode Breakdown:
0:00-0:40: Intro
0:41-1:36: Introduction of Dr. Kristen Pogue
1:37-5:42: VICTORIA trial overview
5:43-8:18: Kristen’s initial thoughts
8:19-9:44: VICTORIA and PARADIGM-HF
9:45-12:17: How does this fit with DAPA-HF results?
12:18-14:14: Vericiguat in the Black population
14:15-15:45: Final thoughts
15:46-16:32: Closing
References:
- VICTORIA Trial: Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020. DOI: 10.1056/NEJMoa1915928.
- PARADIGM-HF Trial: McMurray JJ, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014;371:993-1004.
- DAPA-HF Trial: McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381:1995-2008.
- A-HeFT Trial: Taylor AL, Ziesche S, Yancy C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004;351:2049-2057.
CardioScripts 